Appel Institute for Alzheimer's Disease Research, and Brain & Mind Research Institute, Weill Cornell Medicine, New York City, New York, USA.
New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA.
Clin Genet. 2021 Jan;99(1):111-118. doi: 10.1111/cge.13829. Epub 2020 Aug 26.
The neuronal ceroid lipofuscinoses (NCLs) are at least 13 distinct progressive neurodegenerative disorders unified by the accumulation of lysosomal auto-fluorescent material called lipofuscin. The only form that occurs via autosomal-dominant inheritance exhibits adult onset and is sometimes referred to as Parry type NCL. The manifestations may include behavioral symptoms followed by seizures, ataxia, dementia, and early death. Mutations in the gene DNAJC5 that codes for the presynaptic co-chaperone cysteine string protein-α (CSPα) were recently reported in sporadic adult-onset cases and in families with dominant inheritance. The mutant CSPα protein may lead to disease progression by both loss and gain of function mechanisms. Iron chelation therapy may be considered as a possible pharmaceutical intervention based on our recent mechanism-based proposal of CSPα oligomerization via ectopic Fe-S cluster-binding, summarized in this review.
神经元蜡样脂褐质沉积症(NCLs)是至少 13 种不同的渐进性神经退行性疾病,其特征是溶酶体自体荧光物质脂褐素的积累。唯一通过常染色体显性遗传发生的形式表现为成人发病,有时被称为 Parry 型 NCL。临床表现可能包括行为症状,随后是癫痫发作、共济失调、痴呆和早逝。最近在散发性成人发病病例和显性遗传家族中报道了编码突触前共伴侣胱氨酸-string 蛋白-α(CSPα)的基因 DNAJC5 的突变。突变的 CSPα 蛋白可能通过功能丧失和获得机制导致疾病进展。根据我们最近提出的基于机制的 CSPα 寡聚化的建议,通过异位 Fe-S 簇结合,铁螯合疗法可能被认为是一种可行的药物干预措施,该建议总结在本综述中。